Neurodegenerative disorders associated with anti-IgLON5 antibodies are frequently characterized by sleep behavior disorder and bulbar symptoms (39, 58), but anti-igLON5 disease symptoms has a wider range expressing a clinical picture overlapping with disorders such as Alzheimer’s disease (AD) (59, 60), corticobasal degeneration (CBD) (61) progressive supranuclear palsy (PSP) (62, 63). This evidence concerns the gene IGLON5 and Classical progressive supranuclear palsy.